Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
22 hedge funds and large institutions have $5.76M invested in Talis Biomedical Corporation Common Stock in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.
3% more capital invested
Capital invested by funds: $5.6M → $5.76M (+$157K)
19% less funds holding
Funds holding: 27 → 22 (-5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29.8K |
| 2 |
Renaissance Technologies
New York
|
+$4.3K |
| 3 |
Morgan Stanley
New York
|
+$714 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$298 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$385K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$42.3K |
| 3 |
Jane Street
New York
|
-$14.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.64K |
TLIS Hedge Fund Activity: Q1 2023 in Review
22 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q1 2023, worth a combined $5.76M — up 2.8% from $5.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TLIS and 1 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Millennium Management, adding an estimated $29.8K. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $385K.
- 22 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q1 2023, down from 27 in Q4 2022.
- Funds reported $5.76M of Talis Biomedical Corporation Common Stock stock for Q1 2023, up 2.8% quarter-over-quarter.
- 1 fund opened new Talis Biomedical Corporation Common Stock positions in Q1 2023 and 6 closed out, a net change of -5 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q1 2023 was Millennium Management, an estimated $29.8K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q1 2023 was ArrowMark Colorado Holdings, an estimated $385K sold.
Based on aggregated 13F filings for Q1 2023.